Navigation Links
Treatment for mild asthma leads to improved lung function
Date:3/10/2008

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better dayto-day lung function.

The study published in this months edition of Primary Care Respiratory Journal was conducted over an 11 month period, and compared the effects of inhaled corticosteroids (ICS) and placebo on asthma control in mild asthmatics.

The results of the study raise questions about the current emphasis in asthma treatment which is based largely on controlling symptoms, and which does not advocate ICS treatment for patients with symptoms two days a week or less.

Results showed significant and clinically important treatment benefits on markers such as lung function, airway hyperresponsiveness and exhaled nitric oxide, which are all predictors of the risk of future adverse outcomes such as exacerbations.

Results indicated that a ceiling effect for lung function, often assumed to prevail in mild asthma, does not exist. Even patients whose lung function is over 90% of predicted normal value may have room to further improve their personal best with treatment.

The study also demonstrated subjects receiving placebo were nearly three times more likely to experience a mild exacerbation.

In recent years the emphasis in asthma treatment has been on how well a patients symptoms are is controlled, says Woolcock research leader Assoc. Prof. Helen Reddel.

The patients in this study had asthma that was so mild, with symptoms once a week or less, that they themselves didnt see any benefit in regular preventer treatment, she said.

However for those participants receiving ICS during the study, their lung function was better, they had less airway inflammation and less airway twitchiness. All of these things are predictors of reduction in risk of future adverse outcomes

While were not advocating that every patient with mild asthma should be on preventer medication, the study shows that when we are discussing the risks and benefits of treatment with these patients, we should talk about their risk of future exacerbations as well as whether they will notice any difference in their current symptoms.

In the same way, for patients with high blood pressure, we talk about giving treatment to reduce their risk of stroke in the future rather than whether they will feel any different here and now.

Dr Reddel explains that while the study sample size was small, the measurement of airway twitchiness, airway inflammation and daily spirometry provided information about future risk that is often not possible in larger groups.


'/>"/>

Contact: Lucy Williams
lucyw@woolcock.org.au
61-403-753-028
Research Australia
Source:Eurekalert

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked ... most prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time ... Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: a ... they shared to overcome struggles in life. “Our Mountains to Climb: A Journey of ... a retired teacher and happily married since 1999; the author’s personal experiences drive this ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Three Narrow ... Roads” is the creation of published author, Rev. Dr. Burnett King Sr., is currently ... coach and founder of the Faith Track Club, Inc., a track-and-field program geared towards ...
(Date:8/18/2017)... ... ... “Depressed: Super Heroes of the Bible”: a gripping and potent text that uses ... tales may have on the reader’s life. “Depressed: Super Heroes of the Bible” is ... much of her time enjoying nature and her family in West Virginia. , ...
(Date:8/18/2017)... ... ... “Kingdom Mandate for Kingdom Builders”: a call to walk as citizens of the Kingdom ... of published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., B.A., ... spent three decades training pastors and Christian leaders. He also met his wife, ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
Breaking Medicine Technology: